MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
55.00
-0.66 (-1.18%)
Aug 14, 2025, 1:42 PM - Market open

MLTX Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-176.16-118.94-36.01-49.97-64.37
Depreciation & Amortization
1.831.380.370.160.01
Asset Writedown & Restructuring Costs
----5.82
Stock-Based Compensation
9.387.287.119.6510.86
Other Operating Activities
-4.29-2.53-8.03-14.160.09
Change in Accounts Receivable
-1.73-1.79-0.84-0.07-0.18
Change in Accounts Payable
11.947.151.58-1.311.88
Change in Other Net Operating Assets
-7.38-9.15-6.96-0.23.68
Operating Cash Flow
-166.42-116.59-42.78-55.89-42.21
Capital Expenditures
-0.34-0.52-0.28-0.02-0.06
Investment in Securities
55.79-205.08-24.9-32.32-
Investing Cash Flow
55.45-205.6-25.18-32.34-0.06
Total Debt Issued
73.02---18
Short-Term Debt Repaid
----15-
Total Debt Repaid
----15-
Net Debt Issued (Repaid)
73.02---1518
Issuance of Common Stock
0.3452.78482.450.050.13
Repurchase of Common Stock
-0-0---0.01
Other Financing Activities
0.09-1.47-2.75134.65-
Financing Cash Flow
73.4651.31479.7119.6951.92
Foreign Exchange Rate Adjustments
1.40.13-0.080.010
Net Cash Flow
-36.11-270.74411.6631.479.65
Free Cash Flow
-166.76-117.11-43.06-55.91-42.27
Free Cash Flow Per Share
-2.64-1.86-0.88-1.90-5.39
Cash Income Tax Paid
1.30.150.040-
Levered Free Cash Flow
-114.43-92.06-24.14-32.23-
Unlevered Free Cash Flow
-113.14-92.06-24.14-32.23-
Change in Working Capital
2.82-3.78-6.22-1.585.38
Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q